US-based biotechnology company Cytonics has started a Phase I clinical trial of a new therapeutic for osteoarthritis of the knee.
The first-in-human study aims to evaluate CYT-108, a recombinant protein designed to inhibit proteases that degrade cartilage in arthritic joints.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,